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Introduction {#sec1}
============

L-type calcium channel Ca~V~1.2 plays an essential role in cardiac development and function ([@bib8], [@bib23]). The missense mutations in *CACNA1C* encoding Ca~V~1.2 channel are associated with Timothy syndrome (TS), a multisystem disorder that features long-QT syndrome and syndactyly ([@bib3], [@bib11], [@bib19], [@bib27]). TS patients are treated clinically with β-adrenergic blockers, calcium channel blockers, and sodium channel blockers ([@bib14], [@bib25]). However, these regimens are insufficient to prevent lethal arrhythmias in TS patients ([@bib5], [@bib15], [@bib21]). Therefore, new therapeutics for TS are still needed. Previously, we found that roscovitine, a cyclin-dependent kinase (CDK) inhibitor, could rescue the phenotypes in human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) and neurons from TS patients ([@bib20], [@bib26], [@bib33]). However, the mechanisms whereby roscovitine restores the cardiac functions in TS CMs have not been fully elucidated. In this study, we sought to investigate the mechanisms underlying the beneficial effects of roscovitine on TS CMs and to identify additional therapeutic compounds for TS.

Results {#sec2}
=======

Roscovitine Analog and CDK Inhibitor Tests {#sec2.1}
------------------------------------------

To confirm the cause of this disease and obtain ideal controls for the TS iPSCs, we generated isogenic control iPSCs from the TS iPSCs using TALEN (transcription activator-like effector nuclease) technology, and characterized the isogenic control iPSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}). The isogenic control iPSCs demonstrated a normal karyotype and pluripotency, and the CMs derived from the isogenic control iPSCs showed regular calcium transients in calcium imaging and normal voltage-dependent inactivation percentage values in voltage-clamp recordings, which are comparable with the values in CMs derived from non-isogenic control iPSCs generated from skin fibroblasts of healthy donors ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1J). To search for roscovitine analogs that are more potent or less toxic than roscovitine and explore the mechanisms underlying the effects of roscovitine on TS CMs, we tested 20 roscovitine analogs and four CDK inhibitors with different specificities against CDKs using a contraction assay with MATLAB-based analysis ([@bib12], [@bib33]) and calcium imaging ([Figure 1](#fig1){ref-type="fig"}A). Two rounds of chemical test were conducted to examine the effects of the compounds. The first round of chemical testing was conducted using TS CM clusters isolated from the monolayer CMs to screen and identify the positive compounds that could increase the spontaneous beating rate and decrease the contraction irregularity of the TS CM clusters ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C and [Table S1](#mmc2){ref-type="supplementary-material"}). The subsequent test was conducted using the intact monolayer CMs to validate the beneficial effects of the positive compounds on TS CMs and to eliminate the potential bias that could be caused by isolating the CMs from the original culture ([Figures 1](#fig1){ref-type="fig"}B--1D). From the chemical tests, we identified two roscovitine analogs, CR8 and Myoseverin-B, and two CDK inhibitors, PHA-793887 and DRF053, that had beneficial effects on TS CMs ([Figures 1](#fig1){ref-type="fig"}B--1D and [S2](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc2){ref-type="supplementary-material"}; [Movie S1](#mmc3){ref-type="supplementary-material"}). When we summarized the CDK targets of all positive compounds, it was found that four out of the five positive compounds have been reported to inhibit CDK5 ([@bib2], [@bib4], [@bib17], [@bib18]) ([Figures 1](#fig1){ref-type="fig"}B, [S2](#mmc1){ref-type="supplementary-material"}G, and S2H), suggesting that CDK5 could be involved in the molecular mechanisms underlying TS.Figure 1Summary of Roscovitine Analog and CDK Inhibitor Tests(A) Schematic illustration of roscovitine analog and CDK inhibitor tests.(B) A summary of the CDK targets of the positive roscovitine analogs and CDK inhibitors. Eighteen other roscovitine analogs did not show positive effects (see [Table S1](#mmc2){ref-type="supplementary-material"}). n.d., CDK targets are not yet determined.(C) Representative traces from the MATLAB-based analysis of TS CM contractions before treatment and 2 hr after the treatment of 2 μM CR8.(D) The analysis of contraction irregularity of TS CMs before treatment and 2 hr after the treatment of each positive compound (n = 10 for the chemical compounds and n = 5 for DMSO control from one TS iPSC line; the irregularity value after treatment was normalized to the corresponding irregularity value before treatment for each sample in each group). ^∗^p \< 0.05, ^∗∗^p \< 0.01; Student\'s t test, paired. Ros, roscovitine; Myo-B, myoseverin-B; PHA, PHA-793887.The replicates (n) are independent biological replicates from multiple rounds of experiments. See [Table S2](#mmc1){ref-type="supplementary-material"} for detailed information about the iPSC lines used for each experiment.

The Effects of CDK5 Inhibition on TS CMs {#sec2.2}
----------------------------------------

To examine whether CDK5 inhibition is beneficial for TS CMs, we first constructed a lentivirus containing the dominant negative (DN) mutant of CDK5. We used patch-clamp recordings and calcium imaging to assess the physiological properties of the TS CMs infected with the CDK5 DN lentivirus. The phenotypes of TS CMs include a delayed voltage-dependent inactivation of Ca~V~1.2 channels, abnormal action potentials, and abnormal calcium transients ([@bib26], [@bib33]). The TS CMs with CDK5 DN expression demonstrated a significantly enhanced voltage-dependent inactivation of Ca~V~1.2 channels compared with the CMs without CDK5 DN expression ([Figures 2](#fig2){ref-type="fig"}A--2C). Moreover, the expression of CDK5 DN significantly shortened the paced action potential duration and rescued the abnormal spontaneous action potentials in TS CMs ([Figures 2](#fig2){ref-type="fig"}D, 2E, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B; [Table S3](#mmc1){ref-type="supplementary-material"}). In addition, we examined the effects of CDK5 DN expression on the calcium currents in TS CMs. The results suggest that TS CMs demonstrated more late calcium currents compared with control CMs, and the expression of CDK5 DN significantly reduced the late calcium currents in TS CMs ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E). Finally, CDK5 DN expression alleviated the abnormal spontaneous calcium transients and paced calcium transients, and significantly reduced the calcium transient duration and half decay time in the paced TS CMs ([Figures 2](#fig2){ref-type="fig"}F--2J and [S3](#mmc1){ref-type="supplementary-material"}F--S3M). Overall, the results indicated that CDK5 DN expression could alleviate all the previously reported phenotypes in TS CMs.Figure 2CDK5 Inhibition Alleviated the Phenotypes in TS CMs(A) Representative voltage-clamp recordings of Ba^2+^ currents in the TS CM with (+CDK5 DN) and without (−CDK5 DN) CDK5 DN expression. "1.0 (relative)" means that the data points were normalized to the corresponding peak current value to make the traces.(B) Voltage-dependent inactivation percentage quantification in TS CMs with (n = 19) and without (n = 7) CDK5 DN expression. Data are mean ± SD.(C) The current-voltage relationships of the Ba^2+^ currents in TS CMs with (squares, n = 19) and without (circles, n = 7) CDK5 DN expression are statistically not significantly different.(D) Representative paced (0.2 Hz) action potential recordings in the CDK5 DN lentivirus infected (+CDK5 DN) and uninfected TS CM.(E) Action potential duration at 90% of repolarization (APD90) quantification in the control CMs (n = 10 from three lines) and the TS CMs with (n = 10 from two lines) and without (n = 8 from two lines) CDK5 DN expression (one-way ANOVA with Bonferroni post hoc).(F) Representative Ca^2+^ transient traces of paced (0.5Hz) single TS CM infected with the R-GECO1 lentivirus and the YFP lentivirus or the YFP-CDK5 DN lentivirus. Blue dots indicate electrical pulses (2 ms, bipolar pulse, 4 V). The expression of CDK5 DN alleviated the abnormal paced Ca^2+^ transients in TS CMs. y Axis, ΔF/F~0~ for R-GECO1 (calcium fluorescence indicator).(G--J) The analysis of Ca^2+^ transient duration, half decay time, amplitude, and integrated calcium transients (area under curve) in the paced TS CMs with and without CDK5 DN expression (n = 7 for the group without CDK5 DN, n = 17 for the group with CDK5 DN).(K) Representative voltage-clamp recordings of Ba^2+^ currents in single TS CM with CDK5 DN expression before (blue) and after roscovitine treatment (red, 5 μM, 3 min).(L) Roscovitine did not significantly enhance the voltage-dependent inactivation of Ca~V~1.2 in TS CMs with CDK5 DN expression (n = 9). Data are mean ± SD.(M) Representative recordings of Ba^2+^ currents in the TS CM with (+shRNA) and without (−shRNA) CDK5 shRNA expression.(N) Voltage-dependent inactivation percentage quantification in TS CMs with (n = 13) and without (n = 9) CDK5 shRNA expression.Data in (C), (E), (G--J), and (N) are mean ± SEM. Data were from two lines and Student\'s t test was used for statistics unless otherwise stated. n.s., not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005. The replicates (n) are independent biological replicates from multiple rounds of experiments. See [Table S2](#mmc1){ref-type="supplementary-material"} for detailed information about the iPSC lines used for each experiment.

Next, we examined the effect of roscovitine on the TS CMs infected with the CDK5 DN lentivirus, to investigate whether CDK5 inhibition partially accounts for the therapeutic effects of roscovitine on TS CMs. The results showed that roscovitine did not further enhance the voltage-dependent inactivation of Ca~V~1.2 in TS CMs with CDK5 DN expression, indicating that CDK5 DN expression is sufficient to rescue the delayed voltage-dependent inactivation of Ca~V~1.2 in TS CMs ([Figures 2](#fig2){ref-type="fig"}K and 2L).

To validate our findings using another approach, we designed short hairpin RNA (shRNA) lentiviral constructs that target CDK5 and confirmed the knockdown efficiency of the constructs ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). We then infected TS CMs with the CDK5 shRNA lentivirus and examined the effects of CDK5 shRNA expression on the reported phenotypes in TS CMs. CDK5 shRNA expression significantly enhanced the voltage-dependent inactivation of Ca~V~1.2 in TS CMs ([Figures 2](#fig2){ref-type="fig"}M and 2N). In addition, CDK5 shRNA expression alleviated the abnormal spontaneous calcium transients in TS CMs ([Figures S3](#mmc1){ref-type="supplementary-material"}M and [S4](#mmc1){ref-type="supplementary-material"}D--S4F). The effects of CDK5 shRNA expression on TS CMs were thus similar to the effects of CDK5 DN expression on TS CMs, indicating that CDK5 inhibition is beneficial for TS CMs.

The Molecular Mechanism Underlying the Positive Effects of CDK5-Specific Inhibition on TS CMs {#sec2.3}
---------------------------------------------------------------------------------------------

The positive effects of CDK5-specific inhibition on TS CMs prompted us to investigate its underlying mechanisms. CDK5 has been reported to phosphorylate serine or threonine in two consensus sequences, S/T-P-X-R/H/K and P-X-S/T-P (where X is any amino acid) ([@bib6], [@bib22]). We examined the sequences of Ca~V~1.2 channels and found five consensus sequences located at the II-III loop and the C terminus (C-term), which are conserved in both humans and rodents ([Figure 3](#fig3){ref-type="fig"}A). We generated plasmids containing FLAG-tagged full-length Ca~V~1.2 and YFP-tagged CDK5 for a co-immunoprecipitation (coIP) assay. The coIP results demonstrated a binding of CDK5 with Ca~V~1.2 ([Figure 3](#fig3){ref-type="fig"}B). Next, we generated FLAG-tagged II-III loop and FLAG-tagged C-term of Ca~V~1.2 constructs to repeat the coIP assay, and validated the binding of CDK5 with the two fragments ([Figure 3](#fig3){ref-type="fig"}C).Figure 3Direct Interaction and Phosphorylation between CDK5 and Ca~V~1.2(A) The structure of human Ca~V~1.2/α1c subunit. The G406R mutation and five CDK5 consensus sequences in Ca~V~1.2 are shown.(B and C) Co-immunoprecipitation (IP) was performed using FLAG antibody resins with HEK 293T cell lysates expressing YFP-CDK5 and FLAG-Ca~V~1.2 (B), or FLAG-II-III loop (C), or FLAG-carboxyl terminus (C-term, C). Anti-(α-)human CDK5 and FLAG-tag antibodies were used for immunoblotting (IB).(D) Design of the in vitro kinase assay. The phosphorylation of the substrates by activated CDK5 consumes ATP and produces ADP that is converted into luminescence.(E and F) Wild-type (WT) II-III loop (II-III) and C terminus (C-term) were phosphorylated by CDK5. PHA-793887 (PHA) and the mutagenesis (II-III Mutant \[MT\]: S783G; C-term 4MT: S1742A/S1799A/S1882A/T1958A) blocked the phosphorylation (II-III: n = 3 for both PHA groups and n = 6 for WT and MT groups; C-term: n = 6 for both PHA groups and n = 9 for WT and MT groups). ^∗∗^p \< 0.01, Student\'s t test for WT versus MT/4MT; data are mean ± SEM.(G) Representative recordings of Ba^2+^ currents in control CM with and without CDK5 WT overexpression.(H) CDK5 WT overexpression significantly delayed the voltage-dependent inactivation of Ca~V~1.2 in control CMs (n = 14 for −CDK5 WT group and n = 12 for +CDK5 WT group from two control lines; ^∗∗^p \< 0.01, Student\'s t test; data are mean ± SEM).(I) Representative Ca^2+^ transient traces of control CMs infected with the R-GECO1 lentivirus and the YFP lentivirus (n = 24 from two lines) or the YFP-CDK5 WT lentivirus (n = 20 from two lines). y Axis, ΔF/F~0~ for R-GECO1 (calcium fluorescence indicator).The replicates (n) are independent biological replicates from multiple rounds of experiments. See [Table S2](#mmc1){ref-type="supplementary-material"} for detailed information about the iPSC lines used for each experiment.

To examine whether CDK5 phosphorylates Ca~V~1.2, we designed an in vitro kinase assay. The wild-type II-III loop or the C-term of Ca~V~1.2 was used as the substrates in this assay. We generated mutant II-III loop and mutant C-term constructs with substitutions of serine/threonine to glycine or alanine in all CDK5 consensus sequences as negative controls ([Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H). The phosphorylation of the substrates by CDK5 consumes ATP and produces ADP, which is then converted into luminescence by detection reagents in the assay ([Figure 3](#fig3){ref-type="fig"}D). The luminescence signal was reduced when we added the CDK5 inhibitor, PHA-793887, to the reactions using wild-type II-III loop or C-term as the substrates. Moreover, the luminescence signal was significantly reduced when using mutant II-III loop or C-term as the substrates, compared with using wild-type II-III loop or C-term as the substrates in the kinase reactions. The results indicated the phosphorylation of the II-III loop and the C-term of Ca~V~1.2 by CDK5 in vitro ([Figures 3](#fig3){ref-type="fig"}E and 3F). The remaining signals in the mutant II-III loop and C-term could result from the phosphorylation of p35 by CDK5 ([@bib1]) and/or non-specific phosphorylation of some serine/threonine residues in the mutant II-III loop and C-term. To provide additional support for the in vitro biochemical results, we examined whether wild-type CDK5 overexpression alters Ca~V~1.2 channel functions in control CMs. We observed that wild-type CDK5 overexpression significantly delayed the voltage-dependent inactivation of Ca~V~1.2 ([Figures 3](#fig3){ref-type="fig"}G and 3H) and induced abnormal calcium transients in control CMs ([Figure 3](#fig3){ref-type="fig"}I). Taken together, the results demonstrated that CDK5 potentially affects Ca~V~1.2 functions by direct binding and phosphorylation, and that CDK5 overexpression could result in delayed voltage-dependent inactivation of Ca~V~1.2 in control CMs.

To further explore the signaling pathways underlying the effects of CDK5 inhibition on TS CMs, we measured the mRNA expression of *CDK5* and its activator p35 (*CDK5R1*) and p39 (*CDK5R2*) in control and TS CMs. We found a significant increase in the mRNA expression of p35 (*CDK5R1*) in TS CMs compared with controls ([Figures 4](#fig4){ref-type="fig"}A and 4B). We next measured the expression of EGR1, a transcription factor that regulates p35 transcription ([@bib10], [@bib24]), and observed a significant increase in *EGR1* mRNA expression in TS CMs ([Figure 4](#fig4){ref-type="fig"}C). We found that the increased p35 (*CDK5R1*) mRNA expression led to an increased p35 protein expression and a hyperactivation of CDK5 in TS CMs ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}I--S4K). We then examined the protein expression of ERK ([@bib10], [@bib24]), the upstream regulator of EGR1. The results showed that the expression of phosphorylated ERK was increased in TS CMs, indicating an elevated ERK activity ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}K). Previous reports have established a connection between an increased intracellular calcium concentration and ERK activation in CMs ([@bib29], [@bib34]). Therefore, one of the potential mechanisms in TS CMs is that excessive calcium influx through the mutant Ca~V~1.2 channels causes an increase in ERK activity, resulting in a subsequent induction of EGR1 and an increase in p35 expression. The increased expression of p35 causes CDK5 hyperactivation, which enhances the delayed inactivation of the mutant Ca~V~1.2 channels, leading to more severe phenotypes in the TS CMs. Thus, CDK5 inhibition using CDK5 inhibitors, DN, or shRNA alleviates the phenotypes in TS CMs ([Figure 4](#fig4){ref-type="fig"}E).Figure 4One of the Potential Mechanisms Underlying the Effects of CDK5 Inhibition on TS CMs(A--C) *GAPDH* was used to normalize *CDK5*, *CDK5R1* (p35), *CDK5R2* (p39), and *EGR1* expression in the qPCR analysis (^∗^p \< 0.05, ^∗∗^p \< 0.01; Student\'s t test; data are mean ± SEM). CM samples from four control lines (Ctrl, n = 12 for *CDK5*, *CDK5R1*, *CDK5R2*, and n = 9 for *EGR1* including two isogenic control lines) and two TS lines (TS, n = 14 for *CDK5*, *CDK5R1*, *CDK5R2* and n = 9 for *EGR1*) were tested.(D) Phosphorylated ERK (pERK) and p35 proteins were increased in TS CMs compared with control (Ctrl) CMs.(E) Schematic presentation of the proposed signaling pathway in TS CMs.The replicates (n) for this figure are independent biological replicates from multiple rounds of experiments. See [Table S2](#mmc1){ref-type="supplementary-material"} for detailed information about the iPSC lines used for each experiment.

Discussion {#sec3}
==========

In this study, we used human CMs derived from the iPSCs generated from the skin fibroblasts of two TS patients to identify additional potential therapeutic compounds based on roscovitine, our previously reported lead compound for TS ([@bib26], [@bib33]). We tested the hypothesis that the beneficial effects of roscovitine on TS CMs are associated with its inhibitory effect on CDKs. We revealed a role of CDK5 in the pathogenesis of TS and a mechanism underlying the therapeutic effects of roscovitine on TS CMs, whereby roscovitine exhibits its effects in part by inhibiting CDK5. Roscovitine has been reported to enhance the voltage-dependent inactivation of Ca~V~1.2 with the TS mutation in a heterologous overexpression system ([@bib30], [@bib31], [@bib32]). Compared with the heterologous system, using TS CMs derived from iPSCs allowed us to examine the effects of roscovitine in a more physiologically relevant cardiac environment. Patient-specific iPSCs provided us with the opportunity to identify key mediators such as CDK5, which is involved in the regulation of Ca~V~1.2 channels in CMs. Although there are several recent updates that provide insights into the structural and functional changes in the Ca~V~1.2 channels caused by the TS mutations ([@bib7], [@bib16]) and a few previous reports indicating the potential regulation of Ca~V~1.2 by CDK5 in pancreatic β cells and a neuronal progenitor cell line ([@bib9], [@bib28]), our findings demonstrate that CDK5 plays an important role in regulating Ca~V~1.2 functions in CMs and that the inhibition of CDK5 is beneficial for TS CMs.

There are still some concerns in the studies using human iPSC-based disease models, one of which is that patient-specific iPSC-based models of long-QT syndrome demonstrate relatively prolonged action potentials ([@bib13]) relative to the patients\' QT intervals. Thus, the iPSC-derived CMs do not fully respond to physiologically relevant high pacing frequencies (1--2 Hz) in calcium imaging and action potential recordings. Another concern is that there might be a progression in the disease phenotypes in iPSC-based models of long-QT syndrome over time, and it would be difficult to identify the optimal time points to examine the effects of therapeutic candidates in the patient-specific CMs (See [Supplemental Note](#mmc1){ref-type="supplementary-material"}).

Although we found the role of CDK5 in cardiac calcium channel regulation, exactly how CDK5 regulates Ca~V~1.2 channels via phosphorylation in the II-III loop and C-term remains unclear. Therefore, further investigation is necessary to elucidate the molecular mechanisms by which CDK5 phosphorylates and regulates Ca~V~1.2 channels in CMs. Moreover, based on the consensus sequences targeted by CDK5, CDK5 may have effects on the functions of other ion channels such as HCN4 and Nav1.5, which play important roles in cardiac function. This report provides insights into the molecular bases of cardiac calcium channel regulation and the development of future therapeutics for TS patients.

Experimental Procedures {#sec4}
=======================

In brief, human iPSCs were cultured using a standard feeder-free protocol with Essential 8 medium and Geltrex (Thermo-Fisher/Life Technologies) following the manufacturer\'s instructions. Human control and patient iPSC lines were differentiated into CMs using the monolayer-based in vitro differentiation protocol ([@bib26]). Whole-cell patch-clamp recordings in single CM were conducted using standard methods with voltage and current-clamp modes for measuring L-type Ca^2+^/Ba^2+^ currents and action potentials, respectively. The statistics used for every figure are indicated in the corresponding figure legends. Student\'s t test (paired or unpaired, two tailed) was conducted with the t test functions in Microsoft Excel software. One-way ANOVA with Bonferroni's or Dunnett\'s post hoc analyses for multiple comparisons was conducted with the GraphPad Prism software. All data meet the assumptions of the statistical tests. All samples used in this study were biological repeats, not technical repeats. We did not exclude any samples and results from the analyses in this study.

Additional experimental procedures and detailed methodology are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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